User preference for a portable syringe pump for iloprost infusion.

about

User preference for a portable syringe pump for iloprost infusion.

Item

http://www.wikidata.org/entity/Q40286785

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

User preference for a portable syringe pump for iloprost infusion.

@en

type

Item

label

User preference for a portable syringe pump for iloprost infusion.

@en

prefLabel

User preference for a portable syringe pump for iloprost infusion.

@en

P1476

User preference for a portable syringe pump for iloprost infusion.

@en

P2093

Alberto Farina

http://www.w3.org/2001/XMLSchema#string

Alfredo Maria Lurati

http://www.w3.org/2001/XMLSchema#string

Antonella Laria

http://www.w3.org/2001/XMLSchema#string

Daniela Mazzocchi

http://www.w3.org/2001/XMLSchema#string

Katia Angela Re

http://www.w3.org/2001/XMLSchema#string

Magda Scarpellini

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Marrazza

http://www.w3.org/2001/XMLSchema#string

P2860

Raynaud's phenomenon: a proposal for classification.

Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Pathogenesis of Raynaud's phenomenon.

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis.

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.

Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.

Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.

P304

139-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PROM.S81473

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278046710

http://www.w3.org/2001/XMLSchema#string

P698

26056502

http://www.w3.org/2001/XMLSchema#string

P921

syringe pump

P932

4447001

http://www.w3.org/2001/XMLSchema#string